Skip to content

Research highlights and trends in treating psoriasis, including new AAD guidelines for topical and systemic therapies

Research highlights and trends in treating psoriasis, including new AAD guidelines for topical and systemic therapies 1

Immediate skin responses to laser and light treatments Already read the article? Click here to take the JAAD CME Quiz Please note: the quiz is only available after the first day of the month for the issue in which it was published. F003 – Systemic Immunosuppression in Dermatology: Pre-treatment Workup, Dosing, Monitoring and Prevention of Adverse EffectsNicole Fett, MD, FAAD – Handout. F018 – Translating Evidence into Practice: Acne GuidelinesJonette Elizabeth Keri, MD, PhD, FAAD – Handout. F068 – Pediatric Psoriasis: Systemic Therapy and BeyondKelly M. F119 – Autoimmune Blistering Diseases: What’s New. Psoriasis is associated with physical symptoms including red, scaly, itchy, and painful skin lesions (Langley, Krueger, & Griffiths, 2005), and many patients experience adverse psychological effects, including poor body image, stress, embarrassment, and depression (Feldman, Behnam, Behnam, & Koo, 2005; Young, 2005). By staying abreast of new research and sharing timely information with patients, NPs and PAs can reinforce their knowledge and credibility as competent, if not expert, caregivers. Biologics may be considered as a first-line systemic therapy for patients with moderate-to-severe psoriasis based on clinical need (Hsu et al.

Research highlights and trends in treating psoriasis, including new AAD guidelines for topical and systemic therapies 2Signs and symptoms of psoriasis may include the following:. Transition from conventional systemic therapy to a biologic agent, either directly or with an overlap if transitioning is needed due to lack of efficacy, or with a treatment-free interval if transitioning is needed for safety reasons. Some of the newer drugs used to treat severe psoriasis directly modify the function of lymphocytes. Section 3 (2009) of the AAD guideline discusses topical agents and recommends their use adjunctively but not as monotherapy if the disease is extensive or recalcitrant. Treatments that provide excellent outcomes for many patients with more severe disease are now available. Psoriasis is an often-debilitating, chronic condition characterized by systemic inflammation that causes thick, red, and scaly skin lesions. Reality View of Psoriasis: From Pathogenesis to New Biologic Therapies An Emerging Approach to Individualize the Management of Psoriasis and Its Comorbidities to Improve Patients Outcomes and Quality of Life. These strategies include the application of evidence-based guidelines, increasing patient cost-sharing, requiring prior authorization, incorporating step-therapy protocols, and excluding some medications from coverage plans. While multiple topical and systemic treatments for psoriasis are currently available, little is known about how patients perceive the adequacy of these treatments. One reason, according to a recent article, may be that patient satisfaction hasn’t been studied enough or incorporated into psoriasis practice guidelines.1. Improving patient adherence to psoriasis therapy is best achieved by developing a strong physician-patient relationship of trust, says Dr. What’s the news from AAD on psoriasis and psoriatic arthritis?

Unlike topical, phototherapy, and conventional systemic therapies that do not specifically target the underlying pathogenesis of psoriasis, biologics have been, and continue to be, developed based on identifying therapeutic targets within the immune and inflammatory pathways associated with disease development and progression. Dr. Jason Emer’s involvement in education, teaching and research has facilitated a host of publications and book chapters. As well, perform other aspects of cosmetic and laser dermatology including fillers, neuromodulation, peels, ablative and non-ablative resurfacing, microneeding (with or without PRP), and skin care recommendations. AbstractConsensus recommends a gradual reduction in the frequency or steroid potency of topical corticosteroids following clinical improvement in the treatment of psoriasis, although no established guidelines have been developed. Their research highlights the importance of NK cells in the pathophysiology of psoriasis.


However, other therapies may be used to manage the cosmetic symptoms. From the Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York. Treatment options range from optimized skin care to topical prescription therapies to systemic medications. Atopic Dermatitis Treatments Moving Forward: Report From the AAD Meeting. Comparison of Dermatology and Allergy Guidelines for Atopic Dermatitis Management. Trends in Systemic Psoriasis Treatment Therapies from 1993 Through 2010. Dermatology Research and Practice is a peer-reviewed, open access journal that publishes original research articles, review articles, and clinical studies in all areas of dermatology. Flares of atopic dermatitis are often managed with courses of topical corticosteroids or calcineurin inhibitors. Major symptoms include a history of chronic or relapsing dermatitis, personal or family history of atopy, pruritus, and typical lesional morphology and distribution 11. Emollient therapy may be useful to help maintain skin barrier function and control symptoms of AD, but emollient use alone rarely leads to complete resolution of AD, especially in severe cases.

Mechanistic Insights Into (and Treatments For Moderate-to-severe Psoriasis